Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Oral high dose 1,25(OH)2D3 pulse therapy].

M Matsubara1, H Sugai, Y Taguma

  • 1Department of Nephrology Sendai Shakaihoken Hospital.

Nihon Jinzo Gakkai Shi
|February 1, 1991
PubMed
Summary

High-dose oral calcitriol (1,25(OH)2D3) effectively suppressed parathyroid hormone (PTH) in uremic patients with secondary hyperparathyroidism. However, this treatment also increased calcium levels and blood pressure, requiring further study.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Method and equipment for estimation activity nuclides in samples of finite dimensions.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine·2024
Same author

Nodal cilia-driven flow: Development of a computational model of the nodal cilia axoneme.

Journal of biomechanics·2017
Same author

The host galaxy of a fast radio burst.

Nature·2016
Same author

Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer.

British journal of cancer·2007
Same author

Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma.

British journal of cancer·2007
Same author

Discrete focusing effect of positive ions by a plasma-sheath lens.

Physical review. E, Statistical, nonlinear, and soft matter physics·2005

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Secondary hyperparathyroidism is a common complication in uremic patients.
  • Current treatments for secondary hyperparathyroidism have limitations.
  • Calcitriol (1,25(OH)2D3) is a potential therapeutic agent.

Purpose of the Study:

  • To evaluate the efficacy and safety of high-dose oral calcitriol in treating secondary hyperparathyroidism in uremic patients.
  • To assess the impact of calcitriol on parathyroid hormone (PTH) levels, calcium, and blood pressure.

Main Methods:

  • A study involving 13 uremic patients with secondary hyperparathyroidism.
  • Oral administration of 4 micrograms of calcitriol (1,25(OH)2D3) twice weekly for 4 weeks.
  • Monitoring of intact PTH, serum total and ionized calcium, and blood pressure.

Related Experiment Videos

Main Results:

  • Significant reduction in intact PTH levels observed in patients with initial PTH below 1000 pg/ml.
  • Elevated serum total and ionized calcium levels in responding patients.
  • Increased mean blood pressure and reported mental irritability in several patients.
  • Limited effect on PTH in patients with very high initial PTH levels (>1000 pg/ml).

Conclusions:

  • High-dose oral calcitriol can suppress PTH secretion in uremic patients, particularly those with moderate hyperparathyroidism.
  • The therapy is associated with risks of hypercalcemia and elevated blood pressure.
  • Further research is needed to determine optimal indications and manage adverse effects of calcitriol therapy.